From Jan 2024 Quarterly
"The study completed dosing as planned in December 2023. A number of animals willnow be subject to a ‘recovery period,’ designed to establish whether any effects seenwith ATL1102 administration revert to normal on cessation of treatment. The animalswill then be subject to pathological analysis to fully assess the effects of ATL1102. TheCompany expects to receive a final study report in mid-2024 and expects to discuss theresults with FDA thereafter. Successful completion of the study may allow Percheron to apply in future for special designations with FDA such as Fast Track Designation and Breakthrough Designation"
Nothing more recent has changed from that, so any time in the next couple months.
From Jan 2024 Quarterly"The study completed dosing as planned in...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
-0.001(1.32%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.7¢ | 7.5¢ | $38.88K | 514.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 39300 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 26315 | 1 |
View Market Depth
| Last trade - 15.19pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
-0.001 ( 1.27 %) |
||||
| Open | High | Low | Volume | ||
| 7.6¢ | 7.8¢ | 7.5¢ | 112689 | ||
| Last updated 15.50pm 21/05/2024 ? | |||||
| PER (ASX) Chart |